An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus

被引：0
|
作者：
RA Eisenberg
S Khan
J Stansberry
D Tsai
S Kolasinski
E Rieder
B Kotzin
RJ Looney
C Strieber
D Albert
机构：
[1] University of Pennsylvania,Division of Rheumatology, Department of Medicine
[2] University of Pennsylvania,Division of Hematology
[3] University of Colorado,Oncology, Department of Medicine
[4] University of Rochester,Division of Clinical Immunology, Department of Medicine
[5] University of Colorado,Division of Rheumatology, Department of Medicine
来源：
Arthritis Res Ther | / 6卷 / Suppl 3期
关键词：
Systemic Lupus Erythematosus; Systemic Lupus Erythematosus Patient; Tetanus; Mycophenolate Mofetil; Tetanus Toxoid;
D O I：
10.1186/ar1407
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus
    Iwata, S.
    Saito, K.
    Hirata, S.
    Ohkubo, N.
    Nakayamada, S.
    Nakano, K.
    Hanami, K.
    Kubo, S.
    Miyagawa, I.
    Yoshikawa, M.
    Miyazaki, Y.
    Yoshinari, H.
    Tanaka, Y.
    [J]. LUPUS, 2018, 27 (05) : 802 - 811
  • [2] Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future
    Sfikakis, PP
    Boletis, JN
    Tsokos, GC
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (05) : 550 - 557
  • [3] A pilot study of rituximab (anti-CD20) for refractory systemic lupus erythematosus
    Tanaka, Y.
    Tokunaga, M.
    Nawata, M.
    Nakayamada, S.
    Sawamukai, N.
    Saito, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 360 - 361
  • [4] Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus
    Fukushima, T.
    Dong, L.
    Sakai, T.
    Sawaki, T.
    Miki, M.
    Tanaka, M.
    Masaki, Y.
    Hirose, Y.
    Kuwana, M.
    Umehara, H.
    [J]. LUPUS, 2008, 17 (03) : 210 - 214
  • [5] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    [J]. ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [6] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    [J]. Arthritis Res Ther, 5
  • [7] Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus
    Kotani, T.
    Takeuchi, T.
    Kawasaki, Y.
    Hirano, S.
    Tabushi, Y.
    Kagitani, M.
    Makino, S.
    Hanafusa, T.
    [J]. LUPUS, 2006, 15 (10) : 683 - 685
  • [8] A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus.
    Albert, D
    Khan, S
    Stansberry, J
    Kolasinski, S
    Tsai, D
    Kamoun, M
    Eisenberg, R
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S446 - S447
  • [9] A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus.
    Albert, DA
    Khan, SR
    Stansberry, J
    Tsai, D
    Eisenberg, RA
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (12): : 3659 - 3659
  • [10] Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus
    ten Cate, R
    Smiers, FJ
    Bredius, RGM
    Lankester, AC
    van Suijlekom-Smit, LWA
    Huizinga, TW
    Egeler, RM
    [J]. RHEUMATOLOGY, 2004, 43 (02) : 244 - 245
12345